You are here: Welcome » Remdesivir

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
remdesivir [2022/09/26 06:49]
pamela
remdesivir [2023/03/19 21:10] (current)
liam
Line 1: Line 1:
-======Remdesivir====== +====== Remdesivir ====== 
-**Remdesivir** is a drug developed and marketed by [[Gilead Sciences]] as an [[antiviral]], though has never been approved by the [[FDA]] for that purpose.+ 
 +**Remdesivir** is a drug developed and marketed by [[pharmaceutical_companies:Gilead Sciences]] as an [[antiviral]], though has never been approved by the [[Food and Drug Administration]] for that purpose.
  
 See [[https://www.campfire.wiki/doku.php?id=covid-19:treatments:drug_therapies:remdesivir|Remdesivir's Use During the COVID-19 Pandemic]] See [[https://www.campfire.wiki/doku.php?id=covid-19:treatments:drug_therapies:remdesivir|Remdesivir's Use During the COVID-19 Pandemic]]
- 
-==== FOIA Remdesivir EUA ==== ((https://www.documentcloud.org/documents/7221603-LEOPOLD-FDA-FOIA-Remdesivir-EUA.html))((https://web.archive.org/save/https://www.documentcloud.org/documents/7221603-LEOPOLD-FDA-FOIA-Remdesivir-EUA.html)) 
-{{ ::remdesivir_eua.png?600 |}}  
  
 ===== Safety Profile ===== ===== Safety Profile =====
  
 ==== Evidence of Toxicity ==== ==== Evidence of Toxicity ====
 +
 https://www.lifesitenews.com/news/doctors-are-being-forced-to-use-toxic-medication-to-treat-covid-respiratory-specialist/ https://www.lifesitenews.com/news/doctors-are-being-forced-to-use-toxic-medication-to-treat-covid-respiratory-specialist/
  
 +===== COVID-19 Pandemic =====
  
-==== Wgt Are Hospitals Spending So Much On Ineffective C-19 Treatments ====+Export this material to [[COVID-19 pandemic]]. 
 + 
 +Researchers note that as an antiviral medication, the best use of remdesivir would be early during COVID-19 progression.((May 22, 2021 | Lars Dolkin et al | Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned | [[https://www.mdpi.com/1999-4915/13/6/963|doi.org/10.3390/v13060963]])) 
 + 
 +==== FOIA Remdesivir EUA ====  
 + 
 +((https://www.documentcloud.org/documents/7221603-LEOPOLD-FDA-FOIA-Remdesivir-EUA.html))((https://web.archive.org/save/https://www.documentcloud.org/documents/7221603-LEOPOLD-FDA-FOIA-Remdesivir-EUA.html)) 
 +{{ ::remdesivir_eua.png?600 |}}  
 + 
 + 
 +==== Why Are Hospitals Spending So Much On Ineffective C-19 Treatments ====
  
 Pierre Kory, MD, MPA Pierre Kory, MD, MPA
Line 34: Line 44:
 As if this all weren’t dispiriting enough, we have undoubtedly spent so much on Remdesivir because hospitals have a major financial incentive to administer it. The Centers for Medicare & Medicaid Services established a system that provides a 20% bonus to each hospital’s bill to encourage them to use Remdesivir and other EUA approved high cost, patented medications.((https://pierrekory.substack.com/p/my-realclear-markets-op-ed-on-how)) As if this all weren’t dispiriting enough, we have undoubtedly spent so much on Remdesivir because hospitals have a major financial incentive to administer it. The Centers for Medicare & Medicaid Services established a system that provides a 20% bonus to each hospital’s bill to encourage them to use Remdesivir and other EUA approved high cost, patented medications.((https://pierrekory.substack.com/p/my-realclear-markets-op-ed-on-how))
  
-===== link dump =====+==== LancetGate: “Scientific Corona Lies” and Big Pharma Corruption. Hydroxychloroquine versus Gilead’s Remdesivir  ==== 
 + 
 +Since this article was first published almost two years year ago on July 11, 2020 under the title LancetGate: “Scientific Corona Lies” and Big Pharma Corruption. Hydroxychloroquine versus Gilead’s Remdesivir on July 3, 2020, there has been a virtual censorship of debate on [[:Hydroxychloroquine]] (HCQ) and [[:Ivermectin]] largely directed against medical doctors. 
 + 
 +On May 22, Remdesivir for the Treatment of Covid-19 — Preliminary Report  by [[:National Institute of Allergy and Infectious Diseases]], [[:National Institutes of Health]], was published by the New England Journal of Medicine, (NEJM) 
 + 
 +On June 29, 2020, Dr. [[:Anthony Fauci]], who is the head of NIAID granted the “Greenlight” to Gilead Sciences Inc. despite the fact that the study of the new experimental drug was “preliminary”.The NIH-NIAID sponsored report (May 22) was used to justify a major agreement with Gilead Sciences Inc. 
 + 
 +A $1.6 billion agreement between the HHS and [[:Gilead Sciences]] Inc. was announced on June 29th, 2020 despite the fact that NIH NIAID study published in the NEJM was considered “preliminary”. In the late 1990s, Gilead Sciences Inc was headed by [[:Donald Rumsfeld]] (1997-2001), who later joined the George W. Bush administration as Secretary of Defense (2001-2006). 
 + 
 +In recent developments, there is an ongoing campaign to suppress both Hydroxycholoroquine as well as Ivermectin as effective preventive and curative drugs. 
 + 
 +The objective has been to sustain the vaccination campaign on behalf of Big Pharma. 
 + 
 +A revised version of this article was published as a chapter in the author’s E-book entitled: 
 + 
 +The 2020-21 Worldwide Corona Crisis: Destroying Civil Society, Engineered Economic Depression, Global Coup d’État and the “Great Reset” 
 + 
 +There are recent reports of Covid-19 related deaths of hospitalized patients treated with Remdesivir. ((https://www.globalresearch.ca/controversial-drug-remdesivir-plays-key-role-covid-related-hospital-deaths-dr-ardis/5789345)) ((https://web.archive.org/web/20220815031026/https://www.globalresearch.ca/controversial-drug-remdesivir-plays-key-role-covid-related-hospital-deaths-dr-ardis/5789345)) 
 + 
 +===== Links to sort ===== 
 + 
 +  * March 8, 2023: [[https://odysee.com/@Housatonic:0/555-ep-207-1-3:9|Ep 207.1.3: The horrifying history of Remdesivir (GS5734) that nobody wants to talk about]] by [[Housatonic]]
  
 https://www.npr.org/sections/health-shots/2020/05/08/851632704/putting-a-price-on-covid-19-treatment-remdesivir https://www.npr.org/sections/health-shots/2020/05/08/851632704/putting-a-price-on-covid-19-treatment-remdesivir
Back to top